Stay updated on NC-6004+Pembrolizumab Combination in Head & Neck Cancer Clinical Trial

Sign up to get notified when there's something new on the NC-6004+Pembrolizumab Combination in Head & Neck Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the NC-6004+Pembrolizumab Combination in Head & Neck Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page now displays the study record for a completed trial of nivolumab and radiotherapy for recurrent head and neck squamous cell carcinoma, including its eligibility criteria, interventions, and outcomes.
    Difference
    50%
    Check dated 2026-11-07T12:39:19.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer now identifies the site revision as v3.8.0 instead of v3.7.2. The study record still displays a 403 error.
    Difference
    0.3%
    Check dated 2026-10-31T13:29:29.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces a transition to using “Super Intelligence” instead of “Artificial Intelligence” across NIH content. The clinical trial page content remains an error page.
    Difference
    1%
    Check dated 2026-10-24T13:04:36.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The footer’s displayed ClinicalTrials.gov revision changed from v3.7.1 to v3.7.2, while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T13:58:21.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision number changes from v3.7.0 to v3.7.1, while the page continues to show a 403 error.
    Difference
    0.2%
    Check dated 2026-10-10T14:10:28.000Z thumbnail image
  7. Check
    57 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, replacing the study content with a generic access notice.
    Difference
    19%
    Check dated 2026-09-19T19:25:16.000Z thumbnail image

Stay in the know with updates to NC-6004+Pembrolizumab Combination in Head & Neck Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the NC-6004+Pembrolizumab Combination in Head & Neck Cancer Clinical Trial page.